Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Strong Trading Volume – Time to Buy?

Zealand Pharma A/S (OTCMKTS:ZLDPF) saw an uptick in trading volume on Monday. 3,150 shares traded hands during trading, an increase of 34% from the average daily volume of 2,357 shares. The stock last traded at $37.00 and had previously closed at $35.38.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ZLDPF. Jefferies Financial Group cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Zacks Research upgraded Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a report on Monday, October 12th. Barclays cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Zealand Pharma A/S Stock Up 6.9%

The company has a quick ratio of 13.98, a current ratio of 13.98 and a debt-to-equity ratio of 0.02. The stock has a market cap of $2.65 billion, a price-to-earnings ratio of 6.14 and a beta of 0.99. The business’s fifty day moving average is $39.51 and its two-hundred day moving average is $47.26.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions.

The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.

Zealand Pharma serves international markets through its development and commercial partnerships.